Price Alert

Dyne Therapeutics Inc. (DYN)

NASDAQ: DYN · Real-Time Price · USD

13.24

-0.24 (-1.78%)

At close: Sep 04, 2025, 3:59 PM

13.00

-1.81%

After-hours: Sep 04, 2025, 06:28 PM EDT

-1.78% (1D)

Bid	13
Market Cap	1.88B
Revenue (ttm)	1.57M
Net Income (ttm)	-412.88M
EPS (ttm)	-3.88
PE Ratio (ttm)	-3.41
Forward PE	-4.29
Analyst	Buy

Ask	14.5
Volume	1,722,335
Avg. Volume (20D)	3,114,311
Open	13.43
Previous Close	13.48
Day's Range	13.03 - 13.51
52-Week Range	6.36 - 37.08
Beta	1.08

About DYN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol DYN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for DYN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 week ago

+3.34%

Dyne Therapeutics shares are trading higher after ... Unlock content with Pro Subscription

1 month ago

+7.72%

Dyne Therapeutics shares are trading higher on possible continued strength after the company reported Q2 financial results on Monday.

News

1 month ago · zacks.com

Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect?

The mean of analysts' price targets for Dyne Therapeutics (DYN) points to a 285.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amon...

1 month ago · benzinga.com

These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss

Dyne Therapeutics Inc DYN reported a loss for the second quarter on Monday.

1 month ago · fool.com

Dyne Reports Wider Loss in Fiscal Q2

1 month ago · businesswire.com

Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatm...

2 months ago · benzinga.com

Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday.

2 months ago · seekingalpha.com

Dyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating Upgrade

Upgrading Dyne Therapeutics to 'Buy' due to promising late-stage DM1 and DMD drug candidates and significant unmet need in both indications. Recent management changes and a more measured clinical appr...

2 months ago · businesswire.com

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN

LOS ANGELES--(BUSINESS WIRE)---- $DYN--Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN.